Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Rowe

Showing results (241-250 of 269) with videos related to

Pageof 27
Sort By:
NPJ Regenerative Medicine|November 27, 2025
A ferret model demonstrates sustained fibrosis, restrictive physiology, and airway proximalizationJacelyn E Peabody Lever, Qian Li, Nikoleta Pavelkova, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Plos Genetics|July 30, 2016
Mutation of Growth Arrest Specific 8 Reveals a Role in Motile Cilia Function and Human DiseaseWesley R Lewis, Erik B Malarkey, Douglas Tritschler, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
Nature Communications|December 19, 2018
Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in miceLaura A Hancock, Corinne E Hennessy, George M Solomon, et al.
The Lancet. Respiratory Medicine|February 26, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trialsAhmet Z Uluer, Gordon MacGregor, Pilar Azevedo, et al.
Pageof 27

Showing results (241-250 of 269) with videos related to

Sort By:
Pageof 27
NPJ Regenerative Medicine|November 27, 2025
A ferret model demonstrates sustained fibrosis, restrictive physiology, and airway proximalizationJacelyn E Peabody Lever, Qian Li, Nikoleta Pavelkova, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Plos Genetics|July 30, 2016
Mutation of Growth Arrest Specific 8 Reveals a Role in Motile Cilia Function and Human DiseaseWesley R Lewis, Erik B Malarkey, Douglas Tritschler, et al.
American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
Nature Communications|December 19, 2018
Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in miceLaura A Hancock, Corinne E Hennessy, George M Solomon, et al.
The Lancet. Respiratory Medicine|February 26, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trialsAhmet Z Uluer, Gordon MacGregor, Pilar Azevedo, et al.
Pageof 27